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The prime suspect behind inflammatory 
bowel disease (IBD) has been wrongly 
accused. Work by Hue et al. (page 2473) 
and Kullberg et al. (page 2485) reveals that 
the cytokine IL-12 was merely a cover for 
the real IBD culprit, IL-23. IL-23 promotes 
inflammation by corrupting not only 
adaptive immunity, as previously thought, 
but also the innate immune system.
IL-12, an activator of adaptive immu-
nity via the induction of Th1 cells, is com-
posed of two subunits, p35 and p40. In 
mouse models of intestinal inflammation, 
antibodies against p40 prevent the chronic 
inflammation that occurs in IBD in response 
to intestinal bacteria. Thus, IL-12 was 
considered responsible for driving IBD.
Case closed? Not quite. In 2000, it was 
discovered that p40 can also dimerize with 
p19 to form IL-23. Thus, all studies using 
antibodies against p40, including studies 
of other autoimmune diseases (see J. Exp. 
Med. 201:163), required reevaluation. 
Using mouse models of IBD, Kullberg et 
al. show that mice incapable of producing 
p35 but still able to produce the p40 
subunit develop intestinal inflammation in 
response to bacterial challenge, whereas 
mice that lack IL-23 resist the disease. 
Furthermore, Hue et al. show that an anti-
p19 antibody strongly inhibits bacterially 
induced intestinal inflammation.
IL-23, which shows increased expression 
in mice with intestinal inflammation, was 
previously thought to activate adaptive Th17 
cells only. But here, Kullberg et al. show 
evidence that both Th1 and Th17 cells may 
be overactivated by IL-23. Hue et al. also 
show, using mice that lack B and T lympho-
cytes, that IL-23 can also induce intestinal 
inflammation via the innate immune system. 
It remains to be determined both how IL-23 
controls these diverse responses and what 
leads to its own overexpression in IBD. 
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Heart attack or cancer?
Suppressing the action of lipoxygenases may reduce “bad 
cholesterol” deposition and inflammation in the arteries and 
thereby prevent heart attacks. But doing so might inadvertently 
cause leukemia, warn Middleton et al. (page 2529).
While studying atherosclerosis (artery hardening) using 12/15-
lipoxygenase (12/15-LO) knock-out mice, Ellen Puré’s team made 
an unexpected discovery: the spleens of all the mice were 
enlarged. Closer inspection of the spleens revealed a distinct 
increase in the myeloid cell population—a feature indicative of 
myeloid proliferative disease (MPD). Consistent with this 
leukemia, lymph nodes displayed an abnormal excess of cells, and 
the leukocyte count of peripheral blood was markedly increased.
12/15-LO−/− splenocytes showed increased levels of the Bcl-2 
oncoprotein and reduced nuclear accumulation of the ICSBP 
transcription factor, which represses Bcl-2. Exactly how loss of 
12/15-LO leads to loss of nuclear localization of ICSBP, however, 
is yet to be determined.
The mice were slightly more likely to die early, but the majority 
had no obvious external symptoms even up to one year of age. The 
protracted, chronic phase of the most common form of human 
MPD, chronic myelogenous leukemia (CML), is also usually 
asymptomatic. As a result, CML often goes undiagnosed in the 
chronic phase and becomes apparent only when the disease 
progresses to the more life-threatening “blast” phase (when the 
number of immature white blood cells is extremely high).
Many existing mouse models of CML show rapid 
progression of the disease and are thus relevant for studying 
the blast crisis phase only. But the 12/15-LO−/− mice are a 
potentially valuable model system for studying the entire 
chronic phase as well as disease progression.
12/15-LO−/− mice have long been used in the study of 
atherosclerosis, but other groups possibly overlooked the enlarged 
spleens, says Puré. Even more astounding is that, although reduced 
activity of human lipoxygenases had been reported in human 
leukemia, its direct involvement in the disease had not been studied.
Now that Middleton and colleagues provide stronger evidence 
for the link between MPD and 12/15-LO, researchers and drug 
companies investigating the anti-
atherosclerotic potential of suppressing 
12/15-LO should certainly be on the 
lookout for features 
of leukemia. 
Intestinal inflammation is reduced by 
anti-p19 treatment (bottom).
Myeloproliferation in mice lacking a lipoxygenase (KO) leads to 
bigger spleens.